Regulus Therapeutics slides after co scraps trial of kidney disorder treatment

Regulus Therapeutics

13/10/2021 13:04

** Drug developer's  RGLS.O  shares fall ~28% to 54 cents in
premarket trade; set for their worst day in more than 2 years
    ** Co says it has decided to discontinue development of its
candidate, RGLS4326, to treat a type of inherited kidney
disorder, based on discussions with FDA and data from an
early-stage study
    ** Co says it will advance another candidate, RGLS8429, for
treating a type of inherited kidney disorder in which cysts
develop in the kidneys causing them to lose function over time
    ** Co expects to start human trial for RGLS8429 in the
second quarter of 2022
    ** Up to Tuesday's close, stock had fallen 43.7% YTD 

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com))